Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2025 · 10-Q
Revenue$131.00K$131.00K−74.3% vs Q2 2024 Net Income-$15.38M-$15.38MN/M vs Q2 2024 EPS Diluted-$0.01-$0.01N/M vs Q2 2024 Operating Income-$14,779,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,992,000N/M Margins · derivedOperating margin-11281.7%−7857.4 pt vs Q2 2024
Net margin-11738.9%−8235.2 pt vs Q2 2024
ended Jun 30, 2025 · filed Aug 14, 2025 · 45 d after period end